Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Genelux CorporationNASDAQ: GNLX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 42.8% from a year ago
Cash & equivalents stood at $9.27M at the end of Q1 FY2026, down 42.8% from a year earlier and up 73.9% from the prior quarter. Over 3 fiscal years it compounded at +137.7% a year.
Context
- Cash & equivalents amounted to 28.6% of total assets at the end of Q1 FY2026, down 12.9 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -42.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 5.33M USD
- Year-over-year change
- -37.7%
- 4-year CAGR
- +4.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.33M | -37.7% |
| FY2024 | 2024-12-31 | 8.57M | -9.1% |
| FY2023 | 2023-12-31 | 9.42M | +2272.3% |
| FY2022 | 2022-12-31 | 397K | -91.2% |
| FY2021 | 2021-12-31 | 4.5M | — |
Cash & Equivalents vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -42.8% is the 9th highest of 11, against a peer median of -7.1%.
- Cash & equivalents amounts to 28.6% of total assets for GNLX, versus a peer median of 19.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $194.83M USD | +111.4% | +19.6% | 96.5% | |
| Mar 2026 | $90.77M USD | -24.6% | -21.3% | 25.9% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $71.77M USD | +148.2% | -6.6% | 28.7% |
| Mar 2026 | $65M USD | +29.1% | -21.4% | 97.8% | |
| Mar 2026 | $36.22M USD | -42.0% | -15.6% | 89.2% | |
| Mar 2026 | $35M USD | -72.6% | -10.9% | 12.1% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $20.16M USD | -10.3% | +138.6% | 7.7% |
| Mar 2026 | CHF 19.17M CHF | -4.0% | -5.3% | 13.9% | |
GNLXGenelux Corporation | Mar 2026 | $9.27M USD | -42.8% | +137.7% | 28.6% |
| Mar 2026 | $8.44M USD | +68.2% | +39.9% | 7.8% | |
| Mar 2026 | $5.66M USD | -91.3% | -41.0% | 4.9% | |
| Peer median (excluding GNLX) | — | -7.1% | -8.7% | 19.9% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.5M | 397K | 9.42M | 8.57M | 5.33M |
| Short-term Investments | 0 | 0 | 13.77M | 22.33M | 9.26M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.33M | 1.5M | 1.01M | 653K | 535K |
| Total Current Assets | 5.82M | 1.89M | 24.2M | 31.55M | 15.13M |
| Property, Plant & Equipment (Net) | 2.21M | 1.98M | 3.6M | 3.08M | 3.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 92K | 1.66M | 92K | 92K | 144K |
| Total Non-current Assets | 2.3M | 3.64M | 3.69M | 3.17M | 3.9M |
| Total Assets | 8.13M | 5.53M | 27.89M | 34.72M | 19.03M |
| Account Payables | 4.46M | 6.78M | 3.78M | 5.57M | 4.36M |
| Short-term Debt | 6.16M | 16.4M | 653K | 329K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 4.5M | 170K | 0 | 0 | 0 |
| Other Current Liabilities | 4.11M | 5.16M | 0 | 0 | 0 |
| Total Current Liabilities | 22.48M | 31.63M | 6.55M | 6.9M | 6.23M |
| Long-term Debt | 18.02M | 8.52M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 18.75M | 9.69M | 1.87M | 1.54M | 1.26M |
| Total Liabilities | 41.24M | 41.31M | 8.42M | 8.44M | 7.48M |
| Common Stock | 9K | 9K | 27K | 35K | 38K |
| Retained Earnings | (184.58M) | (189.78M) | (221.52M) | (251.39M) | (283.54M) |
| Accumulated OCI | 2K | 2K | 14K | 64K | 9K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (33.11M) | (35.78M) | 19.47M | 26.27M | 11.54M |
| Total Debt | 25.31M | 26.35M | 2.52M | 1.87M | 1.69M |
| Net Debt | 20.82M | 25.96M | (6.9M) | (6.7M) | (3.65M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.